Geron Corporation (GERN)
Update on Imetelstat Clinical Development Program Conference Call
September 10, 2012 8:30 am ET
Anna Krassowska – Investor and Media Relations
John A. Scarlett – President and Chief Executive Officer
Stephen M. Kelsey – Executive Vice President, Head of Research & Development and Chief Medical Officer
Graham K. Cooper – Executive Vice President, Finance and Business Development and Chief Financial Officer
Karen E. Jay – JPMorgan Chase & Co.
Brian Klein – Stifel Nicolaus & Company, Inc.
Charles Duncan – JMP Securities
Ryan Martin – Lazard Capital Markets
Good day, ladies and gentlemen, and welcome to the Geron’s Conference Call to provide update on Imetelstat Clinical Development Program. My name is Ann and I will be your coordinator for today’s call. At this time, all participants are in listen-only mode. (Operator Instructions) We will be facilitating a question-and-answer session following the presentation.
I would now like to turn the presentation over to your host for today’s call, Anna Krassowska, Investor and Media Relations. Please proceed.
Thank you, Ann. Good morning everyone, and thank you for joining us to hear this update on our clinical development program for imetelstat. With me on the call this morning are Dr. John Scarlett, President and Chief Executive Officer; Dr. Steve Kelsey, Executive Vice President, Head of R&D and Chief Medical Officer; and Graham Cooper, Executive Vice President, Finance and Business Development and Chief Financial Officer.
Following our remarks, we will take questions. The press release issued this morning provided an update on the imetelstat program is available on our website at geron.com. Today’s call is being webcast live on Geron’s website and will be available for replay until October 10.